Biologics License Application (BLA)

Stem cell transplant
#Biologics License Application (BLA) #Clinical trial #FDA

FDA accepts BLA for kidney transplant drug imlifidase

The US Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for a drug desensitising highly sensitised adult kidney transplant patients.  Imlifidase, developed by biopharmaceutical company Hansa Pharma, is a unique IgG cleaving enzyme that rapidly inactivates over 95% of donor-specific antibodies within two to six hours of administration, providing a crucial… Read More

#News #Regulatory

EBV virus
#Atara Biotherapeutics #Biologics License Application (BLA) #Epstein-Barr virus #FDA #Pierre Fabre

Will this Atara Biotherapeutics drug be the first approved therapy of its kind? 

Atara Biotherapeutics has submitted a Biologics License Application (BLA) for Tabelecleucel (Tab-cel), a for treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) with the US Food and Drug Administration (FDA). There are currently no FDA approved therapies in this treatment setting.  It is indicated as monotherapy for treatment… Read More

#News #Regulatory